Compare BridgeBio Pharma Inc (BBIO) vs ProShares UltraPro QQQ ETF (TQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs ProShares UltraPro QQQ ETF — how do they compare? BridgeBio Pharma Inc trades at $84.87 (market cap $16.46B), while ProShares UltraPro QQQ ETF trades at $76.25. The key difference: BridgeBio Pharma Inc is trading nearer its 52-week high, ProShares UltraPro QQQ ETF nearer its low. Which is the better fit depends on your goals.
| BBIO | TQQQ | |
|---|---|---|
Market Cap | $16.46B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $90.17 | $87.22 |
52-Week Low | $44.81 | $37.89 |
Enterprise Value | $18.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
TQQQ, a 3x leveraged ETF tracking the Nasdaq-100, trades at $72.64, down 5.7% in the last 24 hours amid a bearish technical signal. The fund lacks traditional financial ratios as it is not a company, and recent news highlights concerns over volatility amplification and hidden costs. Support is seen at $72, with resistance at $74.
Outlook is cautious due to leveraged structure magnifying losses in downturns; opportunities exist for tactical traders during tech rallies, but risks include daily rebalancing decay and market volatility. Long-term holders face significant drawdown risks, as seen in 2022's 81% drop versus Nasdaq's 33% decline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About ProShares UltraPro QQQ ETF
TQQQ is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Nasdaq-100 Index. It is one of the most liquid and actively traded instruments in the market, designed for sophisticated traders to amplify short-term bullish exposure to large-cap non-financial growth stocks, predominantly in the technology and communication sectors.
Read more on TQQQ →
